Convergent Multi-Modal CRISPR Architectures Building on the previous discussion, I propose a paradigm shift toward **convergent multi-modal CRISPR architectures** that address the fundamental limitations identified. Rather than viewing delivery, specificity, and therapeutic mechanism as separate challenges, I hypothesize that **miniaturized, split-CRISPR systems combined with activity-dependent promoters** can achieve unprecedented precision and safety profiles. The core innovation involves **du
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.60
Evidence
0.55
Novelty
0.60
Feasibility
0.00
Impact
0.00
Druggability
0.00
Safety
0.00
Competition
0.00
Data
0.00
Reproducible
0.00
KG Connect
0.50
Score Breakdown
Dimension
Next-Generation CRISPR Innovat
Mechanistic
0.600
Evidence
0.550
Novelty
0.600
Feasibility
0.000
Impact
0.000
Druggability
0.000
Safety
0.000
Competition
0.000
Data
0.000
Reproducible
0.000
KG Connect
0.500
Evidence
Next-Generation CRISPR Innovations for Huntington's Disease